Avoro Capital Advisors LLC Grows Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Avoro Capital Advisors LLC boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,628,822 shares of the company's stock after purchasing an additional 6,600 shares during the period. Krystal Biotech makes up approximately 5.8% of Avoro Capital Advisors LLC's portfolio, making the stock its 5th biggest holding. Avoro Capital Advisors LLC owned approximately 9.14% of Krystal Biotech worth $411,831,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in KRYS. US Bancorp DE raised its position in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after acquiring an additional 82 shares during the period. Crossmark Global Holdings Inc. raised its holdings in shares of Krystal Biotech by 5.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after purchasing an additional 121 shares during the period. Finally, Perigon Wealth Management LLC raised its stake in Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after buying an additional 123 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KRYS. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Trading Down 0.6 %

Shares of NASDAQ:KRYS traded down $1.06 during midday trading on Friday, reaching $168.06. 171,300 shares of the company were exchanged, compared to its average volume of 295,380. The stock has a market cap of $4.86 billion, a PE ratio of 56.21 and a beta of 0.75. The business's fifty day moving average is $176.14 and its two-hundred day moving average is $171.62. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm earned $0.30 EPS. The business's revenue was up 116.4% on a year-over-year basis. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).